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The EU train keeps on going
Hannes Wahlroos
Professor, Director General
National Agency for Medicines
Editorial
The European Union is often blamed for its secre-
tive and undemocratic policy preparation process,
with lobbyists heavily influencing future develop-
ments. The drafting  process for EU pharmaceutical
policies is in an open phase at the moment, howev-
er, and active players have already had an opportu-
nity to influence matters.
The European Commission is preparing a com-
munication on the future of pharmaceuticals for
human use in Europe. The Commission consulta-
tion paper, with questions, was published  for com-
ments from all stakeholder groups last autumn. A
total of 104 contributions were received, which are
published on the Commission website1. A summary
of the contributions will also be published shortly,
following which a communication by the Commis-
sion to the European Parliament and the Council of
the European Union can still be expected in the
course of this year. Once these reactions have been
received, it is reasonable to expect legislative pro-
posals from the Commission that will define EU
pharmaceutical policies far into the next decade.
The preparation of policies is a process that will
extend over several years.
The challenges surrounding future EU pharma-
ceutical policies this time include the globalisation
of the sector, ensuring the smooth running of the
internal market in a widening Europe, and ad-
vances in science and technology. The key issues in-
clude six themes, the new ones being the preven-
tion of counterfeit medicines and the promotion of
transparency and harmonisation with regard to
pricing and reimbursement practices. 
Familiarity with the contributions is recom-
mended to anyone who would like to know and
learn about the differences in emphasis among the
interests of stakeholders and even Member States
in EU pharmaceutical policies. Even though Fin-
land did not make use of its opportunity to have an
influence last autumn (a majority of the Member
States did not submit a contribution), it would be
wise for those involved in the future policy making
processes to familiarise themselves even at this
stage with the factors that are of importance to the
most active opinion formers. 
The most unconditional support appears to be
for the fight against counterfeit medicines. At-
tempts to liberalise pharmaceutical sales and distri-
bution will certainly be scrutinised in this respect.
The contributions made by European pharma-
ceutical industry organisations are thorough, but in
terms of their content they are incoherently split
according to the interests of each industry group.
The self-medication sector focuses on achieving less
stringent regulation. The innovative pharmaceutical
industry places emphasis on, for example, protect-
ing innovations, the national features of pricing
and reimbursement practices, and on preventing
supranational evaluations of medicines with regard
to their relative efficacy. The generic pharmaceuti-
cal industry would like to increase the use of gener-
ic medicines in Europe. The contributions contain
plenty of useful information about the pharmaceu-
tical markets in Europe.
Contributions were also received from the Euro-
pean doctors’, pharmacists’, wholesalers’ and con-
sumers’ associations and the well-known British
Medical Association (BMA). The viewpoints of the
pharmaceutical industry are taken yet further in
these contributions. Attention is also drawn to the
fact that health-care professionals and consumers
take a very critical view of the role of the pharma-
ceutical industry as the distributor of pharmaceuti-
cal information to consumers. 
Member States in which the pharmaceutical in-
dustry is a significant industry sector did not miss
out on their opportunity to have an influence. In
their contributions, the harmonisation of pharma-
ceutical pricing and reimbursement practices and
evaluation of the relative efficacy of medicines are
generally presented as important issues. The issues
as a whole are nevertheless considered to fall with-
in the competence of the Member States.
According to an old truth about exerting influ-
ence on EU issues, it is considered that the best re-
sults are achieved by comprehensively exerting in-
fluence at the initial stage of preparations. This
method has already been adopted by many.
1 http://ec.europa.eu/enterprise/pharmaceuticals/
pharmacommunication/pubconsult.htm
In the autumn of 2007 the Na-
tional Current Care recommen-
dation was issued for the treat-
ment of ADHD in children and
adolescents (1). The recommen-
dation of the expert group set up
by the Finnish Child Psychiatry
Association, the Finnish Child
Neurology Society and the
Finnish Medical Society Duodec-
im is that primarily non-medical
care should be used in ADHD in
children under school age and in
ADHD in school age children
with mild symptoms. For severe
symptoms medication should be
added if adequate benefit is not
attained with other forms of
treatment. Medication should be
tried if the symptoms of ADHD
cause significant disadvantage in
some particular area of life, for
example in family life, in school,
or in relationships with friends.
In severe problems the medical
treatment combined with psycho-
social therapies can be intro-
duced right away following con-
sultation and the setting of
guidelines.
Medical treatment 
The medical treatment of ADHD
is evidence-based. The efficacy of
methylphenidate, dextroampheta-
mine and atomoxetine has been
proven in several controlled trials
with respect to symptoms of at-
tention deficit, hyperactivity and
impulsiveness.  
The first stimulant therapies
in Finland were introduced in the
1960’s at HYKS Paediatric Out-
patient Clinic for the treatment
of severe cases of MBD. The
longest history of medical treat-
ment for ADHD is found in Nor-
way, where last year about one
per cent of the under 16-year-
olds were receiving medical treat-
ment. This was three times more
than in Finland. The use of med-
ication is still growing in Norway
at the rate of 10% per year (2),
and the same applies to North
America, where already five per
cent of the underaged population
are receiving medical treatment
for their ADHD.
Medical treatment for chil-
dren’s ADHD has increased
rapidly in Finland also. The total
number of paediatric patients in
1999 was 274. In 2005, a total
of 4,343 patients received
methylphenidate or amphetamine
therapy; 2,748 of whom were
under the age of 17. In 2005
stimulants were received by a to-
tal of 4,703 persons, 175 of
whom received atomoxetine and
185 modafinil. In the age group
most frequently on the medica-
tion, the 7 to 14-year-olds, stimu-
lants were given (mostly as long-
acting methylphenidate) on aver-
age to slightly fewer than 1 in
200 children in the year 2005,
i.e. fewer than one in ten paedi-
atric ADHD patients (3).
Among the stimulants, there is
no distinct difference in the effi-
cacy and adverse effects between
short- and long-acting prepara-
tions. Compliance is generally
better with a drug that is taken
once a day, and the risk of a
stimulant’s ending up in the
wrong hands is smaller than that
for a short-acting preparation.
Commonly known adverse reac-
tions including loss of appetite,
sleep disturbances, headache and
abdominal pain; light-headedness
and tiredness are possible. A
stimulant may sometimes trigger
symptoms of tic or epileptic
seizures in those prone to them.
When such reactions occur, it is
usually enough just to replace the
drug with one that is more bene-
ficial in terms of duration of ac-
tion or to adjust the quantity or
time of administration of the
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ADHD medication and adverse drug reactions
Attention-deficit/hyperactivity disorder (ADHD) is a common disorder which restricts the functional 
ability; its key symptoms consist of inability to concentrate, hyperactivity and impulsiveness. ADHD
is one of the most important developmental disorders, both with regard to frequency and prognosis. 
The prevalence of ADHD in international and Finnish studies is 4–8%. Especially in association with 
behavioural disorders and without appropriate treatment it may significantly increase the risk of 
mental disorders, intoxicant abuse and criminality.
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dose. Aids used for falling asleep
including medication with mela-
tonin can be considered. It is sel-
dom necessary to withdraw med-
ication altogether, and even then
it is recommended that another
active agent be tried, similarly to
a situation in which an adequate
response is not achieved. 
It was not until the turn of the
century that atomoxetine, a spe-
cific noradrenaline re-uptake in-
hibitor, was developed to treat
ADHD. New adverse reactions
have consequently emerged in re-
cent years, when the use of the
drug has been growing. The usu-
al adverse reactions caused by
atomoxetine are, especially at the
start of treatment, loss of ap-
petite, gastrointestinal symptoms
and tiredness. The symptoms of
tic are not aggravated by atom-
oxetine and it is not associated
with the risk of abuse. It may,
however, trigger seizures in
epileptics. Liver toxicity may also
occur as a very rare side effect.
The treatment should be discon-
tinued if jaundice occurs or if
laboratory results show evidence
of liver dysfunction, and treat-
ment should not be reintroduced.
Atomoxetine may increase an ag-
gressive or suicidal tendency. Pro-
longation of the QT interval has
also been reported.
Effect on growth 
The therapy is at the beginning
often associated with a loss of
weight which may later revert to
normal. Despite several studies it
has remained unclear how stimu-
lant therapies affect growth. One
review included 21 studies on
children’s growth development
during or after therapy with
methylphenidate or dextroam-
phetamine (4). In nine studies a
statistically significant reduction
in growth rate was found, where-
as no effect was found in twelve
other studies. In two studies the
growth rate was found to in-
crease after discontinuation of
therapy. Researchers estimated
the probable reduction in growth
rate during stimulant therapy to
be as much as 1 cm a year. Even
though the reduction in growth
rate during stimulant therapy is
generally considered insignificant
in comparison with the benefits
of the therapy, the growth rate
should be regularly monitored
during both stimulant and atom-
oxetine therapy. This is impor-
tant especially in infants, in
dwarfism and during the admin-
istration of high doses of stimu-
lants.
Long-term medication
The benefits of ADHD drugs not
diminished as the therapy is pro-
longed. About a third of patients
introduced to this therapy use it
for more than two years, and
over 15% for longer than five
years (5). The longest controlled
trials have lasted for less than
two years and follow-up studies
for three to five years, so knowl-
edge of the benefits and risks of
long-term use is scarce. Perfor-
mance during therapy and life
quality have been shown to im-
prove with therapy, but perma-
nent change in the control of be-
haviour or in learning have not
been proven. 
The lack of long-term moni-
toring has raised concern about
possible adverse effects on chron-
ic treatment. While the treatment
became more popular and the use
among adults increased suspicion
arose, especially in North-Ameri-
ca, of possible severe harmful
cardiovascular effects of ADHD
drugs. Information about the
common occurrence of psychic
reactions in trials involving the
use of long-acting methylpheni-
date caused concern about the
psychiatric harmful effects of
ADHD drug therapy. As a result,
the FDA was even considering at-
taching a warning about cardio-
vascular and psychiatric risks
(black box warning) on the AD-
HD drug packages. Following
careful discussion it was, howev-
er, abandoned, but advice was
given that information about pos-
sible cardiovascular and psychi-
atric risks should be added on the
drug packages.
Adverse cardiovascular 
reactions caused by ADHD
drugs
The majority of ADHD drugs are
sympathomimetics with a stimu-
lant effect also on the cardiovas-
cular system. A high pulse rate
and hypertension are common.
The changes are nevertheless
mild, mostly transient, dose-de-
pendent and clinically of minor
relevance compared with the ben-
efits of the therapy. The pulse
rate and blood pressure should
nevertheless be monitored during
treatment.
The FDA has commissioned a
survey of the cases of sudden
death during ADHD therapy
(short-acting and long-acting am-
phetamine, dextroamphetamine,
methylphenidate and atomoxe-
tine) during the period of
1.1.1992 to 28.2.2005 reported
to the adverse drug reaction reg-
ister (6). The analysis includes all
those deaths which were not
caused by an overdose of medica-
tion, abuse of medication, or by
any other specific reason or med-
ication. The quantity of drugs
used was assessed on the basis of
prescriptions and numbers dis-
pensed by pharmacies, divided in-
to two groups: the under 18-year-
olds and the over 18-year-olds.
The number of sudden deaths
reported in the under 18-year-
olds during amphetamine therapy
was 14 in total (0.3/100,000 pa-
tient years), 13 of which were as-
sociated with the use of long-
term amphetamine–dextroamphe-
tamine therapy. The age of the
patients varied from seven to 16
years, the duration of therapy
from one day to eight years. In
three fatal cases several drugs
had been used. In six cases a car-
diovascular structural defect was
found in autopsy. The cases re-
sulted in the banning of the
preparation of amphetamine–
dextroamphetamine in Canada in
February 2005 until additional
reports were submitted, and the
drug was subsequently reintro-
duced on to the market in August
the same year. The instructions
for use include a warning about
the use in cardiac patients, and a
warning was also added about
abuse which can cause a sudden
death.
Cases of sudden death in the
under 18-year-olds during
methylphenidate therapy num-
bered 11 (0.2/100,000 patient
years). Seven of these occurred
during short-acting and four dur-
ing long-acting methylphenidate
therapy with a dose variation of
18–60 mg/day. The patients were
9 to 15 years of age and had
been using the medication for a
period of two months to ten
years. Five children had at least
had one other medication in use,
one even five medications. Six
children showed cardiovascular
abnormality on autopsy. Not a
single fatal case appeared to be
associated with methylphenidate
either alone or directly.
Three sudden deaths in the
under 18-year-olds during atom-
oxetine therapy were reported
(0.5/100,000 patient years). The
age of the patients varied be-
tween 2.5 years and 12 years, the
period of use of the drug from
six weeks to four months. There
was no evidence of cardiovascu-
lar abnormalities in any of them.
The youngest one was reported
as having also been on another
therapy, the concentration of
which was found on autopsy to
be toxic.  
Studies show that the risk of
sudden death in all 1- to 20-year-
olds is 1.3 to 4.6 deaths per
100,000 lifeyears. The number of
sudden deaths reported during
the use of ADHD drugs has been
smaller than that which would be
expected based on the general
risk of sudden death in children
and adolescents. There are no da-
ta on the assessed general mortal-
ity among children and adoles-
cents with heart failure. Further-
more, nor is there any certain in-
formation about the proportion
of severe adverse reactions that
are reported to the adverse reac-
tion register. Estimations have
been proposed suggesting that
only 1 to 10 percent of severe ad-
verse reactions are reported to
the FDA (7).
Children with a structural
heart defect, cardiomyopathy or
arrhythmia may be at increased
risk of adverse cardiac reactions
or of sudden death. The cardio-
vascular state of these children
should be closely monitored dur-
ing any ADHD therapies, and the
Finnish current treatment recom-
mendations do not advise ADHD
therapy without cooperation with
a paediatric cardiologist.
In healthy children the drugs
are not considered to cause any
special cardiovascular risk. Be-
fore trying the drugs it is never-
theless advisable to check the in-
volvement of any cardiac symp-
toms, such as attacks of syncope
and unconsciousness, palpita-
tions, chest pain, hobbies involv-
ing heavy physical activity which
increase the pulse rate, the use of
other sympathomimetics and a
family history of sudden death,
cardiac death and arrhythmia.
There is no need for cardiac ex-
amination (ECG, echography,
consultation with a cardiologist)
if the patient’s heart is healthy
and symptom-free and the clini-
cal status is normal (growth data,
cardiac auscultation, pulse rate
and blood pressure) and no risk
factors are detected in the pa-
tient’s history. 
The possibility of harmful car-
diovascular effects has been dis-
cussed in the NEJM of 6.4.2006
(7–9). The Journal of Pediatrics
has published a paper discussing
the actions the doctor should
take in this issue (10). A retro-
spective study was published re-
cently in which cardiac deaths
did not occur during stimulant
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therapy (42,612 years) in the
55,384 ADHD patients of the age
of 3 to 20 years (124,932
lifeyears). During the years of
stimulant use, the number of car-
diac symptoms resulting in hospi-
talisation was equal to that
among those with previous use of
stimulants (35,671 years) and
those with no previous use of
stimulants (46,649 years). The
number of patients needing emer-
gency care for some cardiac
symptom, syncope, dysrhythmia,
tachycardia or palpitations, or
blood pressure was 1,091. The
use of a stimulant was associated
with a 20% higher risk for emer-
gency appointments compared
with the non-stimulant users (5). 
Adverse psychiatric reactions 
The FDA carried out a review of
the adverse psychic reactions
caused by ADHD drugs and ob-
served in clinical trials and ad-
verse reaction follow-ups between
1.1.2000 and 30.6.2005.
The randomised controlled
clinical trials (RCT) consisted of
a total of 425 placebo years in
3,990 patients. The ADHD drugs
that were studied had in the
RCTs 770 (N = 4,846) patient
years and in the open label stud-
ies 8001 (N = 13,712) patient
years. Many clinical trials were of
a short duration and a propor-
tion of them had patients en-
rolled who were known to bene-
fit from the drug, which will limit
the relevance of the clinical trials
in the evaluation of drug safety.
The samples were small, dura-
tions of treatment short, events
few, and the reliability of the ad-
verse reaction reports (about re-
maining unchanged, classification
of the adverse reactions) could
not be confirmed during the on-
going trials. 
During placebo therapy no
manic or psychotic symptoms oc-
curred. During active ADHD
therapy in RCTs the different
drugs triggered 0 to 2.8 cases of
psychosis or mania per 100 pa-
tient years. In open label studies
psychotic or manic symptoms
were exhibited to an equal extent
with long-acting methylpheni-
date, atomoxetine, modafinil and
amphetamine-dextroampheta-
mine in 0.2–0.3% of patients. 
During placebo therapy in all
RCTs 0.9 cases of suicidal ten-
dency occurred per 100 patient
years. During atomoxetine thera-
py in RCTs suicidal tendency oc-
curred in 1.5 cases and in open
label studies in 0.9 cases per 100
patient years. According to the
pharmaceutical company Eli Lil-
ly’s own studies, the occurrence
of suicidality in association with
atomoxetine therapy was signifi-
cantly higher (0.4% of the pa-
tients, p < 0.01) in comparison
with the placebo therapy; no sui-
cides actually occurred.
Aggressiveness occurred dur-
ing placebo therapy in 7.1 cases
per 100 patient years. Aggression
decreased during modafinil thera-
py. According to the Marketing
authorisation holder Eli Lilly’s
own analysis, aggressiveness oc-
curred in clinical trials in 1.6%
of patients on atomoxetine thera-
py (N = 1,308), in 1.1% on
placebo therapy (N = 806) and in
0.8% on methylphenidate thera-
py (N = 472).
There were many post-mar-
keting reports of adverse reac-
tions including cases of psychosis,
mania, suicidal tendency and ag-
gressiveness, they were mostly
mild or transient. There are also
several case reports of psychotic
symptoms.
An analysis of the adverse re-
actions did not reveal risk factors
which would predict psychic ad-
verse reactions. New instructions
on the package for use by both
the patient and the doctor are un-
der way. In addition to the warn-
ing about aggravation of a previ-
ous psychosis or mania, the risk
of these even in other patients
should be cautioned about. The
medication can cause visual, sen-
sory and hearing hallucinations.
The package of atomoxetine al-
ready contains warnings about
suicidal tendencies. Children
should be monitored during the
treatment in case of adverse psy-
chiatric reactions, and parents
should be advised to contact a
doctor if the child’s behaviour
changes unexpectedly during
treatment. Several of the harmful
psychiatric reactions caused by
the drug disappear spontaneously
within a couple of days when the
administration is stopped, which
is what should be done, tem-
porarily at least. Aggression can
be part of ADHD, which can be
alleviated by the drug. If new ag-
gression or severe exacerbation
occurs, the therapy should be dis-
continued. In addition to the
FDA website (11, 12) guidelines
are also provided in a paper pub-
lished in American Journal of
Psychiatry (13).
Medication for children and
adolescents with ADHD
Medication can be introduced by
a paediatrician or a paediatric
neurologist, paediatric or adoles-
cent psychiatrist or other doctor
well familiar with the psychic and
physical development of chil-
dren/adolescents. The family and
the child/adolescent should re-
ceive adequate information about
the medication and its aims. The
medical therapy should be consis-
tent, the follow-up should be sys-
tematic and, especially at the
start of the therapy, adequately
concise. Follow-up treatment can
also be taken care of by a prima-
ry healthcare doctor. 
In the choice of drugs consid-
eration should be given to the oc-
currence of symptoms in various
situations and at various times of
the day, as well as to other possi-
ble concurrent problems. Before
prescribing the drug the pre-
scriber should gain familiarity
with current drug-specific in-
structions in respect of con-
traindications and adverse reac-
tions. 
The choice of drug is depen-
dent on any concurrent illnesses
(other psychic symptoms, symp-
toms of tic, Tourette’s syndrome,
epilepsy, sleep disturbances), his-
tory of adverse reactions, treat-
ment compliance, risk of abuse,
the wishes of the child/adolescent
or family, and the price. Upon in-
troduction of the therapy, it will
be decided which changes of
symptoms and functions should
be monitored. The therapy
should always be introduced at a
low dose. The stimulant dose is
then increased, for example
weekly, while the response and
any adverse reactions are con-
comitantly monitored. When ad-
justing the dose a weekly contact
should also be maintained with
those responsible for the treat-
ment, and the decision about
continued therapy should be
made at an appointment visit
within two to three months. The
therapy should aim at achieving
adequate efficacy without caus-
ing any significant adverse reac-
tions.
ADHD medication should be
consistent and, as with all other
medical therapies, monitoring
should be systematic. Compli-
ance can be improved by secur-
ing the continuance of the thera-
py, for example by monitoring at
3–6 monthly intervals. Its effica-
cy and any adverse reactions, as
well as symptoms of concomitant
illnesses, should be monitored;
these are assessed by means of
questionnaires and regular clini-
cal tests and interviews. The
overall situation and the need for
continued medical therapy are
again assessed during follow-up.
In some patients the need for
therapy continues until adult age,
in others the therapy can be dis-
continued as symptoms are alle-
viated and new skills learned.
Studies have shown that the ther-
apy continues for more than two
years in on average a third of the
patients. When discontinuation is
considered in a balanced situa-
tion, an interval with no medica-
tion may for example be intro-
duced, and the extent of the
symptoms and disability experi-
enced by the patient at home, in
school and in other situations
(based on questionnaires and
clinical reviews) are assessed.
Medical therapy can be discon-
tinued when the symptoms no
longer constitute a significant
disability. The continuation of
other forms of treatment is gen-
erally advised.
In the planning of medical
therapy any possible risks should
also always be considered: there
should be awareness of their ex-
istence, and their significance
should be compared with the
benefits of the medical therapy.
Treatment of ADHD offers clear
evidence of benefits, and in addi-
tion to the decrease in the actual
symptoms, reduced abuse and re-
duced risk of accidents can for
example be distinguished. The
current treatment recommenda-
tions are there to assist the clini-
cian in the planning and carrying
out of the overall treatments.
New forms of drugs are being
developed and introduced. The
possibility of abuse is reduced as
drugs which the FDA has already
approved such as the methylphe-
nidate transdermal system (MTS)
and lisdexamfetamine, which is a
precursor of dextroamphetamine
and bio-degradable in the intes-
tines, are introduced on to the
market.
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Adverse drug reactions (ADR)
have also been reported by drug
dispensers, i.e. pharmacists since
2005 as stipulated in the pharma-
ceutical legislation reformed that
year. Prior to this, the guidance
only applied to drug prescribers:
doctors and dentists. Sporadic re-
ports had nevertheless been re-
ceived from pharmacists even be-
fore the legislative reform. In this
paper we discuss the ADR re-
ports submitted by them to Na-
tional Agency for Medicines
(NAM) between 2002 and 2007
in Finland. A total of 141 reports
were received from pharmacies
during that period (Table 1). The
57 of these cases was classified as
serious. No reports of any fatal
cases were received. Adverse re-
actions caused by vaccines are ex-
cluded from this review.
The majority of the reports
were on antimicrobials (12 in to-
tal), antiinflammatory analgesics
(10), antiasthmatics (10) and
antiepileptics and statins, six of
each. The reports involved mostly
a variety of different symptoms
such as headache, dizziness, nau-
sea and skin disorders. The major
single adverse reaction reported
was a rash (Table 2). As a rule,
over half of the reported reac-
tions were expected ADRs, in
other words, they are already
mentioned in the undesirable ad-
verse effects section of SPC of the
particular drug. No reports were
received on the more recent drugs
that had been on the market for
less than two years.
Medical devices 
Pharmacists submitted 16 reports
associated with the function of
medical devices and ADRs that
had occurred in association with
their use. The use of adrenaline
auto-injector had evoked four re-
ports of cases where the injector
did not function normally. In
these reports were also described
the lack of efficacy, delayed ther-
apeutic response and allergic re-
actions. 
Four reports were received on
insulin pens and pumps and six
on asthma inhalators. Reports on
malfunctions of insulin adminis-
tration devices also referred to al-
terations of blood sugar levels,
hyperglycaemia, hypoglycaemia
and, in one case, unconsciousness
associated with low blood sugar.
Correspondingly, together with
malfunctions of inhalators, ADRs
such as exacerbations of asthmat-
ic symptoms, lack of efficacy,
dyspnoea, as well as headache,
palpitations and oral or respira-
tory tract irritation were report-
ed. Most of such problems are
probably caused by incorrect use
of the mechanical device, poor in-
structions for its use or poor
guidance given. Table 3 contains
detailed individual cases pertain-
ing to these ADR reports.
Postcoital contraception
preparations
Postcoital contraception prepara-
tions were released to the OTC
sale (over-the-counter) in 2002 in
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Table 1. ADR reports submitted by 
pharmacies each year.
Year Number
2002 2
2003 0
2004 1
2005 9 *
2006 59
2007 70
*  A new Medicines Act came into force on  
7.11.2005.
Table 2. The most frequently reported 
ADR terms. Singel case report may relate 
to more than one reaction.
ADR Number
Rash 15
Lack of drug effect 11 
Device failure 10
Headache 9
Erythema 7
Dizziness 6
Pruritus 6
Nausea 6
Dyspnoea 5
Cramps legs 5
Oedema legs and hands 5
Pharmaceutical product complaint 5
Table 3. Examples of cases associated with ADR reports on medical devices.
Patient and drug Adverse drug reaction
1) 83-year old male An analgesic patch was twice applied to the patient, with a one day interval because it had become
Durogesic prolonged detached . The patient’s pain became worse, and he was consequently admitted to a  hospital. About
released patch a week after the event, while still in hospital, the patient noticed that the patch had again become 
detached and it was found in the bed. A nurse had attached the patch which had become detached. 
The marketing authorisation holder carried out investigations due to a suspected product defect. 
Nothing out of the ordinary, however, was found in the batch of drugs. 
2) 4-year-old female While prick tests were being carried out the patient suffered an anaphylactic reaction. The  Epipen 
Epipen auto-injector auto-injector  was placed ready for use, but it was not until after force had been applied at the third 
attempt that this was successful. The child returned to full consciousness. The child sat in a chair 
thereafter and attempts were made to administer adrenaline without success. The girl was placed in 
supine position, and by applying enormous force Epipen was successfully activated. The child was 
admitted to hospital.
3) 36-year-old male The patient was unable to activate Epipen auto-injector as required for an allergic reaction. His level 
Epipen auto-injector of consciousness started to drop and his girl friend decided to drive him to the hospital. On the way 
to hospital the patient’s level of consciousness dropped further, and he had for example difficulties 
in identifying traffic signs. Once in hospital he received appropriate treatment for an allergic 
reaction (including intravenous fluid balance correction and cortisone). He spent the night in hospi-
tal and made a full recovery.
4) 40-year-old female It was not until on the fourth attempt that the patient was able to activate Epipen auto-injector in 
Epipen auto-injector response to an allergic reaction. In previous similar situations she had always succeeded on the first 
attempt. She recovered from breathing problems immediately when she managed to inject the 
adrenaline into herself.
5) Female, age unknown According to the patient, when pressure was applied the spray was too quickly exhausted after  
Imigran nasal spray which the drug had no effect all. She had used the same drug for years. The specific medicinal spray 
was sent for an examination to the marketing authorisation holder, but no explanation to support 
the patient’s description was found. Therefore, it could be a case of incorrect use.
6) Female, age unknown For her insulin pump, the patient bought 4 x 10 ml Novorapid injections from the pharmacy. No 
Novorapid injection problems emerged with the first two vials. On the third day she noticed, however, that there were 
problems with the efficacy of the insulin. She replaced the container, but her condition did not 
improve. Then she took a third vial of Novorapid injection from the fridge but it had no effect. She 
was taken in for first aid treatment due to high blood sugar concentrations (measured by herself: 
33 mmol/l). At the first aid unit insulin was administered  and her state returned to normal. The 
insulins were sent to the marketing authorisation holder, but no defects were found. The insulin 
had not been exposed to sunlight and it had not been frozen.
7) 64-year old female The patient noticed that her asthma inhaler did not function well and she felt that the drug was
Seretide diskus ineffective. The inhaler was sent to the marketing authorisation holder, but no defects were found.
inhalation powder
8) Male, age unknown A non-smoking patient complained that his asthmatic symptoms were getting worse when there  
Seretide diskus were ten doses left. The same had happened already three times before (all of the doses had the 
inhalation powder same batch number). The patient had suffered from asthma for years. All of the four powder 
inhalers were sent to the marketing authorisation holder, but no defects were detected.
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Finland. This is also evident in
the drug consumption, as their
use initially doubled and has
since stabilised to reflect the level
of use in 2003.
A total of five unintended
pregnancies associated with the
use of a postcoital contraception
preparation have been reported
to NAM. Four of these reports
were received from pharmacies
between 2002 and 2007 (Table
4), in other words only one re-
port has been received from else-
where than pharmacies. Evaluat-
ing by the descriptions received,
postcoital contraception was car-
ried out appropriately.
In conclusion 
The number of ADRs submitted
by pharmacies during the review
period between 2002 and 2007 is
small and does not as such enable
us to draw accurate conclusions
or especially make any kind of
safety comparisons between dif-
ferent medicinal substances. For
example, in 2006 a total of 1,045
reports were received on ADRs,
59 of which, i.e. less than 6%
were submitted by pharmacists.
The reports submitted by them
do nevertheless reflect the role of
pharmacy as an important point
of contact and source of informa-
tion to the client especially with
regard to OTC medicines such as
postcoital contraception prepara-
tions and antiinflammatory anal-
gesics. Moreover, in the case of
malfunction of the medical device
the patient’s natural contact is the
pharmacy that dispensed the drug
with the device, and that is where
the report of a possible malfunc-
tion or ADR will be reported.
NAM wishes to thank all
those healthcare professionals
who have submitted ADR re-
ports. It is important to report
any suspected ADRs, since espe-
cially rare ADRs and interactions
may not emerge until the drug is
widely used and the treatment
covers various patient groups.
Busy pharmacists should also re-
member to advise their clients to
discuss ADRs with their own
doctors as necessary; the doctor
may then also submit an ADR re-
port. Suspected ADRs should be
reported especially when the reac-
tion is serious, it is a suspected
interaction, unexpected adverse
reaction, or in the case of a more
recent drug that has been on the
market for not more than two
years, or where according to the
person submitting the report the
frequency of the reaction appears
to have increased.
Table 4. ADR reports received from pharmacies, involving patients who had become pregnant despite the use  according to instructions of a
postcoital contraception product
Adverse drug reaction
1) 24-year old female took a postcoital contraception pill (750 micrograms) within less than two days following intercourse and 
an other pill within about 3 days of it. When her period did not start as usual, she carried out a pregnancy test which was positive. 
The pregnancy was confirmed on ultrasound examination and was not terminated. 
2) 27-year old female took a postcoital contraception pill (750 micrograms) within 10 and 22 hours from unprotected intercourse. 
A pregnancy test a month later proved positive. The report was made one and a half months following the use of the pill and up 
until then termination of pregnancy had not been planned.  
3) 30-year old female took a postcoital contraception pill (1.5 milligrams) 32 hours following unprotected intercourse. Following 
administration of the drug the patient had no diarrhoea or vomiting. About a month after the use of the postcoital contraception 
product the patient carried out a pregnancy test twice, both tests being positive. Nothing is known regarding continuation of the 
pregnancy.
4) 38-year old female took a postcoital contraception pill (1.5 milligrams) within about a day following intercourse. Despite this, 
she became pregnant. The patients underwent an abortion.
